8:00 am Registration & Morning Coffee

8:50 am Chairs’ Opening Remarks

Selecting Optimal Models for Determining Your ADC Toxicity Profile

9:00 am Understanding Underlying Mechanisms of Action to Accurately Determine Class Effects of Different Payloads & How They Will Translate


  • Looking into mechanisms of action of different ADCs to determine toxicities
  • Applying this understanding to the development of your ADC candidates
  • Widening your understanding of how your drug will translate to humans in the clinic

9:00 am Development of Acute Rodent Models to Establish Surrogate Endpoints for Clinically Relevant Toxicities

  • Ronnie Yeager Project Director/Toxicologist, Emerging Therapeutic Platforms, Abbvie


  • Delving into acute rodent toxicity model development
  • Looking into corneal toxicity as a case study
  • Understanding liver sinusoidal injury as a clinical toxicity

9:30 am Morning Refreshments & Networking


This session is an opportunity to connect with peers working on ADC drug development and hold in-depth conversations with some of the brightest minds to establish meaningful and lasting relationships.

10:30 am Designing NHP studies to define ADC toxicities that are translatable to the clinic


  • How to use known payload class effects to design an informative NHP safety evaluation
  • Maximizing your toxicology study while reducing NHP use to obtain the most relevant safety information
  • Determining when toxicity is on-target or off-target using dermal toxicity as a case study

11:00 am Choosing the Most Appropriate Models for Your Preclinical ADC Toxicity Study

  • Sylvain Thierry Head of Pharmacology Immuno-Oncology & Targeted Therapies, Mablink


• Deciding the most relevant species based on your target and ADC for toxicity

• Selecting the most appropriate species to conduct your toxicity studies in

• Determining if humanized models are always the most representative choice for safety

11:30 am Lunch & Networking

Informing Clinical Trial Design & Toxicity Monitoring Using Preclinical Data

1:00 pm Evaluating Preclinical Study Findings & Determining Appropriate Outline for Clinical Trial Design to Minimize Toxicity


  • Designing more robust clinical studies with relevant preclinical findings
  • Determining the relevance of preclinical data when translated into a human in the clinic
  • Expecting toxicities more accurately in the clinic based on your preclinical findings

1:30 pm Nonclinical & Clinical Toxicity Assessment of ELU001, a C’Dot Drug Conjugate (CDC) Targeting Folate Receptor Alpha


  • Deep diving into a case study of a C’Dot Drug Conjugate
  • Selecting appropriate models to determine safety profiles
  • Looking at what has been seen in the trial relating to learnings from tox studies

2:00 pm Afternoon Refreshments & Scientific Poster Session


The scientific poster session will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere.

Mitigating ADC Related Toxicities in the Clinic to Expand Therapeutic Windows

3:00 pm A Case Study on Ocular Toxicities: How to Mitigate a Known Toxicity in the Clinic

  • Grace Lytle Executive Ocular Medical Director, ImmunoGen


  • Underlining the mechanisms of action and how ocular toxicity comes about with ADC treatments
  • Discussing how the mitigation and management strategies for ocular toxicity with developed
  • Successes of mitigating this common toxicity and how it has allowed increases in dosage and subsequently efficacy

3:30 pm Understanding Toxicities Associated with Developing ADCs for Gynaecological Cancers: A Case Study on Mirvetuximab Soravtansine


  • Looking into the unique toxicity related challenges when developing ADCs for Gynaecological disorders
  • Delving into the case study of Mirvetuximab Soravtansine for treating ovarian cancer
  • Learning how to manage these toxicities in the clinic

4:00 pm End of Scientific Program Day One